|Articles|October 31, 2022
Massive Bio Onboards Over 100,000 Cancer Patients
Company exceeds enrollment goal for its AI platform.
Advertisement
Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.
Read more about the platform and its enrollment
.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
Breaking Out of AI Pilot Mode in Clinical Development
3
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
4
ACT Brief: Community Sites Prove Readiness, Platformization Reshapes Clinical Ops, and AI Targets Precision Care at JPM
5